Even in 2019, there is no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a final diagnosis of Autism. However, these medical tests are often done in order to look for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a lot of information has been found on the main components of the endocannabinoid system, a rather complex ensemble of lipid signals and their intended receptors, purported transporters, and metabolic enzymes.
This research shows that the eCB receptor signaling plays a key role in many human health and disease conditions of the central nervous system, thus opening the avenue to the therapeutic exploitation of eCB-oriented drugs for the treatment of psychiatric, neurodegenerative, and neuroinflammatory disorders. This also gives a view of the eCB system, and alterations of its main components in human patients and animal models relevant to ASD. As long as autism number continue to skyrocket, CBD will play a pivotal role in research of the disorder.